Baclofen/samidorphan

Drug Profile

Baclofen/samidorphan

Alternative Names: ALKS-29; ALKS-33/baclofen; Baclofen/ALKS-33

Latest Information Update: 26 Sep 2011

Price : $50

At a glance

  • Originator Alkermes
  • Class Aminobutyric acids; Drug withdrawal therapies; Small molecules
  • Mechanism of Action GABA B receptor agonists; Opioid mu receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Alcoholism

Most Recent Events

  • 05 Dec 2008 Alkermes initiates a Phase-I trial for Alcoholism in the USA
  • 31 Jul 2008 Phase I/II development is ongoing in the US
  • 06 Jul 2007 Results from a phaseI/II clinical trial in patients with alcoholism added to the adverse events and Drug Withdrawal therapeutic trials sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top